Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health utilizing its compounds. Its development activities are focused on its lead compound, anatabine citrate. Anatabine citrate is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids and non-steroidal anti-inflammatories. Its lead compounds have shown preclinical in vitro and in vivo ability to modulate the expression of specific inflammatory molecules considered relevant to many chronic inflammatory disease states.